TherapeuticsMD, Inc. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026.

Key Highlights

  • Net income of $741 thousand for the nine months ended September 30, 2026, compared to net income of $50 thousand for the same period in 2025, according to the filing.
  • License revenue of $2,852 thousand for the nine months ended September 30, 2026, up from $2,129 thousand in the prior-year period.
  • Cash and cash equivalents of $10,447 thousand as of September 30, 2026, compared to $7,483 thousand at December 31, 2025.
  • Total assets of $37,932 thousand as of September 30, 2026, versus $37,656 thousand at December 31, 2025.
  • Accumulated deficit of $951,650 thousand as of September 30, 2026, reduced from $952,391 thousand at December 31, 2025.
  • 11,574,362 shares of common stock outstanding as of November 9, 2026, per the filing cover page.

TherapeuticsMD Reports Continuing Operations Results for Q3 and Nine Months of 2026

According to the filing, TherapeuticsMD, Inc. (NASDAQ:TXMD) reported net income from continuing operations of $501 thousand for the three months ended September 30, 2026, compared to $50 thousand for the same quarter in 2025. For the nine-month period, income from continuing operations was $768 thousand, versus a loss of $41 thousand in the prior-year nine-month period. The company's sole revenue line from continuing operations is license revenue, which totaled $1,259 thousand in the third quarter of 2026, up from $784 thousand in the third quarter of 2025.

The filing disclosed that total operating expenses for the nine months ended September 30, 2026, were $4,870 thousand, slightly below the $4,967 thousand reported for the same period in 2025. General and administrative expenses were nearly flat year over year at $4,571 thousand versus $4,560 thousand. Other income contributed materially to the period's results: sublease income was $1,561 thousand and miscellaneous income was $1,038 thousand for the nine months ended September 30, 2026, the filing stated.

On the balance sheet, the company reported total stockholders' equity of $27,624 thousand as of September 30, 2026, up from $26,876 thousand at December 31, 2025. Net cash provided by continuing operating activities was $2,991 thousand for the nine months ended September 30, 2026, compared to $2,079 thousand for the same period in 2025, according to the cash flow statement. The company also reported a loss from discontinued operations of $27 thousand for the nine-month period, net of income taxes.

What Was Disclosed

TherapeuticsMD filed its Form 10-Q for the quarter ended September 30, 2026, disclosing nine-month net income of $741 thousand, license revenue of $2,852 thousand, cash of $10,447 thousand, and total assets of $37,932 thousand, with 11,574,362 shares outstanding.